PMID- 38400680
OWN - NLM
STAT- MEDLINE
DCOM- 20240226
LR  - 20240227
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 13
IP  - 3
DP  - 2024 Feb
TI  - Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as 
      neoadjuvant treatment in locally advanced gastric or gastroesophageal junction 
      cancer: A phase II, single-arm study.
PG  - e7006
LID - 10.1002/cam4.7006 [doi]
LID - e7006
AB  - PURPOSE: In the present study, we aimed to evaluate the efficacy and safety of 
      camrelizumab combined with oxaliplatin plus S-1 in patients with resectable 
      gastric or gastroesophageal junction cancer. METHODS: In this single-arm, phase 
      II clinical trial, patients with locally advanced gastric or gastroesophageal 
      junction adenocarcinoma were enrolled to receive three cycles of neoadjuvant 
      camrelizumab and oxaliplatin plus S-1 every 3 weeks, followed by surgical 
      resection and adjuvant therapy with the same regimen. The primary endpoint was 
      pathological complete response (pCR) (ypT0) rate and secondary endpoints were R0 
      resection rate, total pCR (tpCR, ypT0N0) rate, major pathological response (MPR) 
      rate, downstaging, objective response rate (ORR), disease control rate (DCR), 
      event-free survival (EFS), overall survival (OS), and safety. RESULTS: Between 
      September, 2020 and January, 2022, a total of 29 patients were enrolled in the 
      present study, all of whom completed neoadjuvant therapy and underwent surgery. 
      Three (10.3%) (95% CI: 2.2-27.4) patients achieved pCR as well as tpCR, 20 
      (69.0%) patients had MPR and 28 (96.6%) patients achieved R0 resection. 
      Treatment-emergent adverse events (AEs) of any grade were observed in 24 (82.8%) 
      patients. Immune-related adverse events of any grade were reported in 13 (44.8%) 
      patients, whereas no grade 3 or higher adverse events occurred. CONCLUSION: The 
      neoadjuvant therapy with camrelizumab in combination with oxaliplatin and S-1 
      showed a modest pCR rate, and favorable MPR rate and safety profile in patients 
      with gastric or gastroesophageal junction cancer.
CI  - (c) 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Zhong, Wen-Jin
AU  - Zhong WJ
AD  - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian 
      Medical University, QuanZhou City, Fujian, China.
FAU - Lin, Jian-An
AU  - Lin JA
AD  - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian 
      Medical University, QuanZhou City, Fujian, China.
FAU - Wu, Chu-Ying
AU  - Wu CY
AD  - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian 
      Medical University, QuanZhou City, Fujian, China.
FAU - Wang, Jiantian
AU  - Wang J
AD  - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian 
      Medical University, QuanZhou City, Fujian, China.
FAU - Chen, Jun-Xing
AU  - Chen JX
AD  - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian 
      Medical University, QuanZhou City, Fujian, China.
FAU - Zheng, Huida
AU  - Zheng H
AD  - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian 
      Medical University, QuanZhou City, Fujian, China.
FAU - Ye, Kai
AU  - Ye K
AUID- ORCID: 0000-0001-8567-6197
AD  - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian 
      Medical University, QuanZhou City, Fujian, China.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 04ZR38536J (Oxaliplatin)
RN  - 73096E137E (camrelizumab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - *Neoadjuvant Therapy
MH  - Oxaliplatin
MH  - Esophagogastric Junction
MH  - *Stomach Neoplasms/drug therapy
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Antibodies, Monoclonal, Humanized
PMC - PMC10891470
OTO - NOTNLM
OT  - Camrelizumab
OT  - Neoadjuvant therapy
OT  - S-1
OT  - gastric cancer
OT  - gastroesophageal junction cancer
OT  - immune checkpoint inhibitor
COIS- The authors declare no conflict of interests.
EDAT- 2024/02/24 11:46
MHDA- 2024/02/26 06:45
PMCR- 2024/02/24
CRDT- 2024/02/24 04:23
PHST- 2023/11/02 00:00 [revised]
PHST- 2023/07/25 00:00 [received]
PHST- 2024/01/31 00:00 [accepted]
PHST- 2024/02/26 06:45 [medline]
PHST- 2024/02/24 11:46 [pubmed]
PHST- 2024/02/24 04:23 [entrez]
PHST- 2024/02/24 00:00 [pmc-release]
AID - CAM47006 [pii]
AID - 10.1002/cam4.7006 [doi]
PST - ppublish
SO  - Cancer Med. 2024 Feb;13(3):e7006. doi: 10.1002/cam4.7006.